Positions

Overview

  • Suzanne Oparil, MD, FACC, FAHA, FASH, FAPS is Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology, and Director of the Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine at the University of Alabama at Birmingham (UAB).

    Dr. Oparil is a cardiologist with a special interest in the fundamental mechanisms of cardiovascular disease and in applying this information to the development of novel treatments. She was involved in early research of the fundamental mechanisms of vascular disease and has made many groundbreaking observations that have greatly impacted clinical medicine.

    Dr. Oparil served as president of the American Heart Association (AHA), the American Society of Hypertension (ASH), and was the first female president of the American Federation for Clinical Research (AFCR). She has held important advisory positions with the NIH, including task forces, expert panels, peer-review and guidelines committees. She has received numerous lectureships and distinguished awards for her contributions to academic medicine. She serves on editorial boards of a variety of medical journals and is member of numerous prestigious organizations in academic medicine.

    Dr. Oparil plays an essential role in the development of cardiovascular research training at UAB. She has mentored numerous students and fellows, many of whom now lead academic programs at prestigious institutions throughout the country. Dr. Oparil is a remarkable leader in hypertension research and continues to break new ground in cardiovascular research
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Sex Differences in Hypertension and Stroke Risk in the REGARDS Study: A Longitudinal Cohort Study 2019
    2019 Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence 2019
    2019 Association of intensive vs standard blood pressure control with cerebral white matter lesions 2019
    2019 Lower Blood Pressure Thresholds Raise the Bar in Pregnancy 2019
    2019 The PARAGON Heart Failure trial–ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction 2019
    2019 Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited 2019
    2019 Epicardial Adipose Tissue and Cardiovascular Disease 2019
    2019 Prevention of Heart Failure in Hypertension—Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study 2019
    2019 Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hypertension 2019
    2019 Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT 2019
    2019 Urinary biomarkers of tubular damage are associated with mortality but not cardiovascular risk among systolic blood pressure intervention trial participants with chronic kidney disease 2019
    2019 Treatment of Resistant and Refractory Hypertension 2019
    2019 Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension? 2019
    2019 Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial 2019
    2019 New data on antihypertensive drugs and risk of cancer: should we worry? 2019
    2019 Blood Pressure and the Electronic Health Record: A Work in Progress 2019
    2019 Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension: The Survey of PatIents with treatment ResIstant hyperTension study 2019
    2019 Induced pluripotent stem cell-derived endothelial cells attenuate lipopolysaccharide-induced acute lung injury 2019
    2019 Out-of-Clinic Sympathetic Activity Is Increased in Patients With Masked Uncontrolled Hypertension 2019
    2018 PTH, FGF23, and intensive blood pressure lowering in chronic kidney disease participants in SPRINT 2018
    2018 Obesity and Pulmonary Hypertension 2018
    2018 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension 2018
    2018 Effect of sleeve gastrectomy on hypertension 2018
    2018 Association of Clinical and Social Factors with Excess Hypertension Risk in Black Compared with White US Adults 2018
    2018 Novel Medical Treatments for Hypertension and Related Comorbidities 2018
    2018 Number of measurements needed to obtain a reliable estimate of home blood pressure: Results from the improving the detection of hypertension study 2018
    2018 Prognostic value of myocardial perfusion imaging performed pre-renal transplantation: post-transplantation follow-up and outcomes 2018
    2018 Revisiting ASCOT 16 years later 2018
    2018 Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study 2018
    2018 Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: Reconciling results from ACCORD BP and SPRINT 2018
    2018 Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants 2018
    2018 Take a blood pressure pill or benefit from renal denervation? 2018
    2018 Visceral Adipose Tissue Accumulation and Residual Cardiovascular Risk 2018
    2018 Final Farewell to Alberto Zanchetti MD. 2018
    2018 Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure 2018
    2018 Case of refractory hypertension controlled after aortic and mitral valve replacement and coronary artery bypass grafting 2018
    2018 In memoriam: Alberto Zanchetti. 2018
    2018 O-linked β-N-acetylglucosamine modification of A20 enhances the inhibition of NF-κB (nuclear factor-κB) activation and elicits vascular protection after acute endoluminal arterial injury 2018
    2018 Reply 2018
    2018 Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial) 2018
    2018 Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension fromthe Systolic Blood Pressure InterventionTrial 2018
    2018 Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease 2018
    2018 Hypertension 2018
    2018 New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden? 2018
    2018 Accuracy of blood pressure measurement devices in pregnancy: A systematic review of validation studies 2018
    2018 VEGF nanoparticles repair the heart after myocardial infarction 2018
    2018 Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions 2018
    2018 Impact of intensive versus standard blood pressure management by tertiles of blood pressure in SPRINT (Systolic Blood Pressure Intervention Trial) 2018
    2018 Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumes 2018
    2018 Sprinting toward the optimal blood pressure target for hypertensive patients 2018
    2018 What is the most appropriate target SBP in persons with hypertension and diabetes mellitus? 2018
    2017 The Matrikine Acetylated Proline-Glycine-Proline Couples Vascular Inflammation and Acute Cardiac Rejection 2017
    2017 Renal denervation in hypertension: is it the end or the beginning of a SPYRAL? 2017
    2017 Baseline quality of life and risk of stroke in the ALLHAT study (antihypertensive and lipid-lowering treatment to prevent heart attack trial) 2017
    2017 Risk stratification of sudden cardiac death in hypertension 2017
    2017 Masked Hypertension 2017
    2017 Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials 2017
    2017 Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT) 2017
    2017 Effects of intensive BP control in CKD 2017
    2017 Regression of Left Ventricular Mass After Bariatric Surgery 2017
    2017 White-Coat Effect Is Uncommon in Patients with Refractory Hypertension 2017
    2017 Cost-effectiveness of intensive versus standard blood-pressure control 2017
    2017 Effect of intensive blood-pressure treatment on patient-reported outcomes 2017
    2017 Incident cardiovascular disease among adults with blood pressure <140/90 mm Hg 2017
    2017 Hypertension in Women: Recent Advances and Lingering Questions 2017
    2017 Race and sex differences in ambulatory blood pressure measures among HIV+ adults 2017
    2017 The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke 2017
    2017 Distinctive Risk Factors and Phenotype of Younger Patients with Resistant Hypertension: Age is Relevant 2017
    2017 Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women 2017
    2017 123I-mIBG scintigraphy: Clinical tool for assessing renal sympathetic activity? 2017
    2017 Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial 2017
    2017 Hypertension and Its Complications in a Young Man with Autoimmune Disease 2017
    2017 Induced pluripotent stem cell-derived endothelial cells overexpressing interleukin-8 receptors a/b and/or c-c chemokine receptors 2/5 inhibit vascular injury response 2017
    2017 The INTERSALT Study and the complex relationship between salt intake and blood pressure 2017
    2017 The technical report on sodiumintake and cardiovascular disease in low- and middleincome countries by the joint working group of theWorld Heart Federation, the European Society of Hypertension and the European Public Health Association 2017
    2017 Assessment of vascular function in low socioeconomic status preschool children: a pilot study 2017
    2017 On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults with Isolated Systolic Hypertension 2017
    2017 Pathophysiology and Potential Non-Pharmacologic Treatments of Obesity or Kidney Disease Associated Refractory Hypertension 2017
    2017 The Global Burden of Disease Study 2015 and Blood Pressure 2017
    2017 11-beta dehydrogenase type 2 activity is not reduced in treatment resistant hypertension 2017
    2017 Association between chronic kidney disease and cancer mortality: A report from the ALLHAT 2017
    2017 Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults secondary analysis of a randomized clinical trial 2017
    2016 Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 2016
    2016 Smad3-mSin3A-HDAC1 Complex is Required for TGF-β1-Induced Transcriptional Inhibition of PPARγ in Mouse Cardiac Fibroblasts 2016
    2016 Blood Pressure in 2016: increased impact factor and change of editors 2016
    2016 Orthostatic changes in systolic blood pressure among SPRINT participants at baseline 2016
    2016 Should Patients with Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target?: A Protagonist View from the SPRINT Trial (Systolic Blood Pressure Intervention Trial) 2016
    2016 BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out? 2016
    2016 Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients with Resistant Hypertension 2016
    2016 The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease 2016
    2016 OS 24-04 A PILOT STUDY ASSESSING THE FEASIBILITY OF VASCULAR FUNCTION IN LOW SOCIOECONOMIC STATUS PRESCHOOL CHILDREN. 2016
    2016 OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX. 2016
    2016 OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX. 2016
    2016 SY 11-3 HYPERTENSION IN WOMEN: MORE DANGEROUS THAN IN MEN? 2016
    2016 SY 11-3 HYPERTENSION IN WOMEN: MORE DANGEROUS THAN IN MEN? 2016
    2016 The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale 2016
    2016 The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 2016
    2016 Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years a randomized clinical trial 2016
    2016 HOPE-3 and SPRINT: two landmark trials with different outcomes? 2016
    2016 Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement 2016
    2016 Refractory hypertension: A novel phenotype of antihypertensive treatment failure 2016
    2016 Urinary sodiumexcretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status 2016
    2016 Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement 2016
    2016 CardioPulse. The SPRINT trial results 2016
    2016 The SPRINT trial results 2016
    2016 Visit-to-visit variability of BP and CKD outcomes: Results from the ALLHAT 2016
    2016 Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial 2016
    2016 Targeted delivery of human iPS-ECs overexpressing IL-8 receptors inhibits neointimal and inflammatory responses to vascular injury in the rat 2016
    2016 SPS3 Evidence Supports Intensive Blood Pressure Control 2016
    2016 Ambulatory blood pressure monitoring in individuals with HIV: A systematic review and meta-analysis 2016
    2016 SPRINT Trial Results: Latest News in Hypertension Management 2016
    2016 The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg 2016
    2016 Cardiovascular care for older adults: Hypertension and stroke in the older adult 2016
    2016 Impact of renal denervation on patients with obstructive sleep apnea and resistant hypertension – Insights from the SYMPLICITY HTN-3 trial 2016
    2016 Should Antihypertensive Treatment Recommendations Differ in Patients with and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]) 2016
    2015 A randomized trial of intensive versus standard blood-pressure control 2015
    2015 An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial 2015
    2015 Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure, and mortality a cohort study 2015
    2015 Estrogen and cardiovascular disease: Is timing everything? 2015
    2015 Apparent treatment-resistant hypertension among individuals with history of stroke or transient ischemic attack 2015
    2015 Tribute: John H. Laragh, MD 2015
    2015 Treatment of Hypertension in Patients with Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension 2015
    2015 Less-tight versus tight control of hypertension in pregnancy 2015
    2015 Less-tight versus tight control of hypertension in pregnancy 2015
    2015 Treatment of hypertension in patients with coronary artery disease: A scientific statement from the american heart association, american college of cardiology, and american society of hypertension 2015
    2015 Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy 2015
    2015 Regional Heterogeneity in 3D Myocardial Shortening in Hypertensive Left Ventricular Hypertrophy: A Cardiovascular CMR Tagging Substudy to the Life Study. 2015
    2015 Predictors of blood pressure response in the SYMPLICITY HTN-3 trial 2015
    2015 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension the SYMPLICITY HTN-3 trial 2015
    2015 Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack 2015
    2015 Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial 2015
    2015 Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension 2015
    2015 Is Blood Pressure Control for Stroke Prevention the Correct Goal?: The Lost Opportunity of Preventing Hypertension 2015
    2015 John H. Laragh, MD 2015
    2015 New Approaches in the Treatment of Hypertension 2015
    2015 Refractory hypertension: Evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure 2015
    2015 Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension 2015
    2015 Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension 2015
    2014 Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in hispanic/latino patients with hypertension: The trinity study 2014
    2014 Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007-2010 2014
    2014 Low sodium intake - Cardiovascular health benefit or risk? 2014
    2014 Determination of prevalence, risk factors, and comorbidities in a large, population-based cohort 2014
    2014 Hypertension Management by Practice Guidelines 2014
    2014 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8) 2014
    2014 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth joint national committee (JNC 8) 2014
    2014 A controlled trial of renal denervation for resistant hypertension 2014
    2014 Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function 2014
    2014 Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality 2014
    2014 Chlorthalidone versus hydrochlorothiazide in hypertension treatment: Do we have the evidence to decide? 2014
    2014 Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: Results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial 2014
    2014 Estrogen effects on vascular inflammation are age dependent: Role of estrogen receptors 2014
    2014 Guidelines for managing high blood pressure - Reply 2014
    2014 Impact of renal denervation on 24-hour ambulatory blood pressure: Results from SYMPLICITY HTN-3 2014
    2014 Incident ESRD and treatment-resistant hypertension: The reasons for geographic and racial differences in stroke (REGARDS) study 2014
    2014 Inhibiting C-reactive protein for the treatment of cardiovascular disease: Promising evidence from rodent models 2014
    2014 Proceedings from Duke resistant hypertension think tank 2014
    2014 Rates, amounts, and determinants of ambulatory blood pressure monitoring claim reimbursements among Medicare beneficiaries 2014
    2014 Renal denervation in treatment-resistant hypertension-Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials 2014
    2014 Response to should more significance be granted to medication response to antihypertensives in patients with resistant hypertension? 2014
    2014 Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease 2014
    2014 Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT 2014
    2014 Targeted delivery of pulmonary arterial endothelial cells overexpressing interleukin-8 receptors attenuates monocrotaline-induced pulmonary vascular remodeling 2014
    2014 The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The systolic blood pressure intervention trial (SPRINT) 2014
    2014 The use of ambulatory blood pressure monitoring among Medicare beneficiaries in 2007-2010 2014
    2014 Trends in hypertension prevalence, awareness, treatment, and control among us adults 80 years and older, 1988-2010 2014
    2014 Update on Clinical Guidelines for Treatment of Hypertension 2014
    2014 Updated guidelines for management of high blood pressure in Japan 2014
    2013 Author Response to Lipid-Lowering in African Americans in ALLHAT-Optimism Bias? 2013
    2013 Hypertension in women 2013
    2013 Novel strategies for treatment of resistant hypertension 2013
    2013 Revisiting the pre-hypertension debate: Increasing evidence for treatment-or not 2013
    2013 Risk of Hospitalized Gastrointestinal Bleeding in Persons Randomized to Diuretic, ACE-Inhibitor, or Calcium-Channel Blocker in ALLHAT 2013
    2013 The Human Side of Failed Hypertension Treatment 2013
    2013 Blood pressure lowering effect of renal sympathetic denervation or placebo? - Building expectations for Symplicity-HTN 3 2013
    2013 Relationships between metrics of visit-to-visit variability of blood pressure 2013
    2013 Prevalence of apparent treatment-resistant hypertension among individuals with CKD 2013
    2013 2013 European society of hypertension/European society of cardiology hypertension guidelines 2013
    2013 Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT) 2013
    2013 Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: A TRINITY subanalysis 2013
    2013 Ovarian hormones and vascular disease 2013
    2013 Primary cardiovascular prevention by Mediterranean diet - The PREDIMED trial 2013
    2013 Endothelial cells overexpressing IL-8 receptor reduce cardiac remodeling and dysfunction following myocardial infarction 2013
    2013 Mortality and morbidity during and after antihypertensive and lipid-lowering treatment to prevent heart attack trial: Results by sex 2013
    2013 Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m2 2013
    2013 Reply to Visit-to-Visit Blood Pressure Variation: Time to Reanalyze All The Data From the TROPHY Study 2013
    2013 Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency 2013
    2013 Association Between Antihypertensive Medication Adherence and Visit-to-Visit Variability of Blood Pressure 2013
    2013 Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus 2013
    2013 The contributions of unhealthy lifestyle factors to apparent resistant hypertension: Findings from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study 2013
    2013 Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism 2013
    2012 Angiotensin receptor - Neprilysin inhibiton (ARNI) A novel therapeutic concept for management of hypertension and heart failure 2012
    2012 J Curve in Hypertension 2012
    2012 Blood Pressure Measurement Device, Number and Timing of Visits, and Intra-Individual Visit-to-Visit Variability of Blood Pressure 2012
    2012 Direct renin inhibitors in hypertension Approaching the moment of truth 2012
    2012 Vasorelaxing effects of estetrol in rat arteries 2012
    2012 Acute O-GlcNAcylation prevents inflammation-induced vascular dysfunction 2012
    2012 Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPLICITY HTN-3 trial 2012
    2012 Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease 2012
    2012 Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study. 2012
    2012 Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: The trinity randomized, double-blind, 12-week, parallel-group study 2012
    2012 Estrogen modulates NFκB signaling by enhancing IκBα levels and blocking p65 binding at the promoters of inflammatory genes via estrogen receptor-β 2012
    2012 Long-Term renal and cardiovascular outcomes in antihypertensive and Lipid-Lowering treatment to prevent heart attack trial (ALLHAT) participants by baseline estimated GFR 2012
    2012 Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial 2012
    2012 Management of hypertension in the elderly 2012
    2012 Transforming growth factor-β regulates endothelin-1 signaling in the newborn mouse lung during hypoxia exposure 2012
    2012 Endothelial cells overexpressing interleukin-8 receptors reduce inflammatory and neointimal responses to arterial injury 2012
    2012 Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: A subpopulation analysis of the TRINITY study 2012
    2012 Long-Term Efficacy and Safety of Triple-Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension 2012
    2012 Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension the ALLHAT diabetes extension study 2012
    2012 Antiplatelet therapy for transient ischemic attack 2012
    2012 Increased time varying heart rate and cardiovascular risk in hypertension Benefit of selective I (f) channel inhibitor? 2012
    2012 Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients 2012
    2012 Kidney disease: Improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease 2012
    2012 Mortality and morbidity during and after the antihypertensive and lipid-lowering treatment to prevent heart attack trial 2012
    2012 Prevalence and Correlates of Low Medication Adherence in Apparent Treatment-Resistant Hypertension 2012
    2012 Refractory hypertension: Definition, prevalence, and patient characteristics 2012
    2012 Renal sympathetic denervation for treatment of hypertension 2012
    2012 Within-Visit Variability of Blood Pressure and All-Cause and Cardiovascular Mortality Among US Adults 2012
    2011 24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy 2011
    2011 An appropriate SCORE to assess cardiovascular risk in hypertension? 2011
    2011 Can catheter-based renal denervation be used safely and effectively to substantially reduce blood pressure in treatment-resistant hypertensive patients? 2011
    2011 Hypoxia induces downregulation of PPAR-γ in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-β signaling 2011
    2011 Introduction 2011
    2011 Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care 2011
    2011 Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) 2011
    2011 Renal nerve ablation: Emerging role in therapeutics 2011
    2011 cGMP inhibits TGF-β signaling by sequestering Smad3 with cytosolic β2-tubulin in pulmonary artery smooth muscle cells 2011
    2011 O-GlcNAc modification of nfκb p65 inhibits tnf-α-induced inflammatory mediator expression in rat aortic smooth muscle cells 2011
    2011 The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension 2011
    2011 Transforming growth factor-β inhibits myocardial PPARγ expression in pressure overload-induced cardiac fibrosis and remodeling in mice 2011
    2011 High mortality explained by mildly elevated blood pressure in Scandinavian adolescent conscripts A plea for early drug treatment? 2011
    2011 Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone 2011
    2011 Response to intervisit blood pressure variability and outcome: Is heart rate a missing confounder? 2011
    2011 ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the american college of cardiology foundation task force on clinical expert consensus documents 2011
    2011 ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the American college of cardiology foundation task force on clinical expert consensus documents 2011
    2011 Rationale for the use of multiple blockers of the renin-angiotensin- aldosterone system in specific patient populations 2011
    2011 The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy 2011
    2011 Treatment of high blood pressure in acute stroke - The SCAST Study 2011
    2011 Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 Update: A guideline from the American Heart Association 2011
    2011 Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: A Guideline from the American Heart Association 2011
    2011 New challenges in blood pressure goals and assessment 2011
    2011 The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: Findings from NHANES III, 1988 to 1994 2011
    2011 ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Developed in Collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, 2011
    2011 Adherence and persistence with taking medication to control high blood pressure. 2011
    2011 Antihypertensive therapy and cancer risks? 2011
    2011 Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: Results in racial/ethnic subgroups 2011
    2011 Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy 2011
    2010 Cardiovascular risks in HIV patients 2010
    2010 Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: Impact of age and gender 2010
    2010 Long-term efficacy of a combination of amlodipine and olmesartan medoxomilhydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: A substudy of the COACH trial 2010
    2010 Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted? 2010
    2010 Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex 2010
    2010 Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension 2010
    2010 Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: A preliminary report 2010
    2010 Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study 2010
    2010 A stitch saves time and lowers blood pressure 2010
    2010 C-reactive protein-mediated vascular injury requires complement 2010
    2010 Prevention of Microalbuminuria in Patients With Type 2 Diabetes: What Do We Know? 2010
    2010 The transcription factor ETS-1 mediates proinflammatory responses and neointima formation in carotid artery endoluminal vascular injury 2010
    2010 Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: A prospective clinical study 2010
    2010 Editorial: Blood pressure and migration 2010
    2010 Editorial: Hypertension research into the new millennium 2010
    2010 ASH position paper: dietary approaches to lower blood pressure. 2010
    2010 Combination therapy in hypertension. 2010
    2010 Treatment of hypertension in patients with diabetes--an update. 2010
    2010 When and how to use self (home) and ambulatory blood pressure monitoring. 2010
    2010 Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction 2010
    2010 Inhibition of transforming growth factor-β signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart 2010
    2010 Angiotensin receptor blockers and cancer - Relationship dismissed by VALUE data while waiting for EMA and FDA reports 2010
    2010 Editorial: Blood Pressure celebrates 20 years of dedication to Nordic hypertension research 2010
    2010 Editorial: Blood pressure variability: Emerging role in risk assessment and therapeutics 2010
    2010 Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes 2010
    2010 Prehypertension: Epidemiology, consequences and treatment 2010
    2009 Does GISSI-AF change the concept of using RAS inhibitors in the primary prevention of atrial fibrillation in hypertensive patients? 2009
    2009 The J-curve phenomenon revisited 2009
    2009 Editorial: Critical aspects in hypertension diagnosis and treatment 2009
    2009 Editorial: Should we treat prehypertension? 2009
    2009 Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: The Losartan Intervention for Endpoint reduction in hypertension study 2009
    2009 Reduction of blood pressure in patients with treatment-resistant hypertension 2009
    2009 Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors 2009
    2009 Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors 2009
    2009 An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension 2009
    2009 Safety and tolerability of fixed-dose irbesartanhydrochlorothiazide for rapid control of severe hypertension 2009
    2009 Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: Evaluation by baseline hypertension stage and prior antihypertensive medication use 2009
    2009 ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses: Reply 2009
    2009 Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: Results from a randomized trial 2009
    2009 Hypertension in the Elderly 2009
    2009 ONTARGET, TRANSCEND and PROFESS - Clarifying, confusing or misleading? 2009
    2009 ASH Position Paper: Dietary approaches to lower blood pressure. 2009
    2009 Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. 2009
    2009 ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses 2009
    2009 Hormone therapy of premature ovarian failure the case for "natural" estrogen 2009
    2009 Loss of Thy-1 inhibits alveolar development in the newborn mouse lung 2009
    2009 Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension 2009
    2009 Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: An emerging strategy in hypertension therapy 2009
    2009 Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: The Losartan Intervention for Endpoint reduction in hypertension study 2009
    2009 Estrogen and mechanisms of vascular protection 2009
    2009 Sleep Apnea, Aldosterone, and Resistant Hypertension 2009
    2009 A true champion of Hungarian kidney research and nephrology education--tribute to László Rosivall. 2009
    2009 Critical aspects in hypertension diagnosis and treatment 2009
    2009 Diastolic dysfunction and heart failure with preserved ejection fraction: rationale for RAAS antagonist/CCB combination therapy 2009
    2009 EXCEED: Exforge®-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: Study rationale, design, and participant characteristics 2009
    2009 Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension 2009
    2009 Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study 2009
    2009 Protein O-GlcNAcylation: A new signaling paradigm for the cardiovascular system 2009
    2008 Benefits of hypertension management in diabetes: An opportunity not to be missed 2008
    2008 Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective 2008
    2008 More focus on therapeutic targets and improved tolerability in hypertension 2008
    2008 Aliskiren and valsartan in stage 2 hypertension: Subgroup analysis of a randomized, double-blind study 2008
    2008 ASH position paper: Treatment of hypertension in patients with diabetes - An update 2008
    2008 Hypertension in women 2008
    2008 Management of older hypertensive patients 2008
    2008 More focus on therapeutic targets and improved tolerability in hypertension. 2008
    2008 Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients 2008
    2008 Renin Inhibitors: Novel Agents for Renoprotection or a Better Angiotensin Receptor Blocker for Blood Pressure Lowering? 2008
    2008 Role of oxygen availability in CFTR expression and function 2008
    2008 Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: American perspective 2008
    2008 Renin inhibition: Should it supplant ACE inhibitors and ARBS in high risk patients? 2008
    2008 More is less? Optimal combination therapy for adequate blood pressure lowering in hypertension 2008
    2008 Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: A losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy 2008
    2008 Fixed combinations in the management of hypertension: Patient perspectives and rationale for development and utility of the olmesartan - Amlodipine combination 2008
    2008 A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET 2008
    2008 Urgent need to address quality control issues of out-of-office blood pressure measurement and patient risk assessment 2008
    2008 Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury 2008
    2008 Thiazide-induced dysglycemia: Call for research from a working group from the national heart, lung, and blood institute 2008
    2008 Transforming growth factor-β signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung 2008
    2008 Characterization of resistant hypertension: Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion 2008
    2008 Achieving better blood pressure control 2008
    2008 Achieving better blood pressure control. 2008
    2008 Beyond brachial pressure effect. 2008
    2008 A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension 2008
    2008 Effects of losartan in women with hypertension and left ventricular hypertrophy: Results from the Losartan Intervention For Endpoint reduction in hypertension study 2008
    2008 Mechanisms and treatment of resistant hypertension 2008
    2008 Atrial natriuretic peptide inhibits transforming growth factor β-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts 2008
    2008 Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension 2008
    2008 ASH 2008: "Living the Vision" 2008
    2008 Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (FcγRI)-dependent 2008
    2008 Role of matrix metalloproteinase-2 in newborn mouse lungs under hypoxic conditions 2008
    2007 Hypertension: What it is; What it isn't; How to think about it, to prevent it, and to manage it 2007
    2007 Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy 2007
    2007 Hypertension: what it is; what it isn't; how to think about it, to prevent it, and to manage it. Interview by George D. Lundberg. 2007
    2007 Hypertension and cardiovascular disease: Is arterial stiffness the heart of the matter 2007
    2007 Aldosterone excess and resistance to 24-h blood pressure control 2007
    2007 Dual inhibition of the renin system by aliskiren and valsartan 2007
    2007 New ESH/ESC Guidelines signal progress in hypertension management 2007
    2007 A Good Year 2007
    2007 Where are we going? Beyond JNC 7. 2007
    2007 Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke 2007
    2007 Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial 2007
    2007 Blood pressure control - Slowly getting there through new strategies? 2007
    2007 The role of endothelin-1 in human hypertension 2007
    2007 Are current guidelines optimal for treatment of blood pressure in patients with coronary artery disease? 2007
    2007 Estrogen modulates TNF-α-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-β activation 2007
    2007 Mechanisms and treatment of resistant hypertension 2007
    2007 Documentation of endpoint prevention with combination therapy in hypertension is urgently needed 2007
    2007 A Major Paradigm Shift 2007
    2007 Aliskiren and valsartan for antihypertensive therapy 2007
    2007 The ALLHAT study revisited: do newer data from this trial and others indicate changes in treatment guidelines? 2007
    2007 Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention 2007
    2007 Does improving hypertension control involve more than just pills?: Commentary 2007
    2007 Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update 2007
    2007 Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries 2007
    2007 An Open Letter to ASH Members 2007
    2007 Evidence-based guidelines for cardiovascular disease prevention in women: 2007 Update 2007
    2007 Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy 2007
    2007 ANP signaling inhibits TGF-β-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells 2007
    2007 Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. 2007
    2007 Endothelin-1 Mediates Hypoxia-Induced Increases in Vascular Collagen in the Newborn Mouse Lung 2007
    2007 JASH Inaugural Issue 2007
    2007 Renin inhibitors in the management of hypertension. 2007
    2006 Beta-blockers as sub-optimal treatment for hypertension: Time for first-line therapy revision? 2006
    2006 The question of whether diabetes and its cardiovascular risks can be prevented: A realistic DREAM? 2006
    2006 Is there a new treatment for hypertensive disease in the horizon? Role of soluble guanylate cyclase 2006
    2006 Proteasomal inhibition: A novel pathway for prevention of atherosclerosis and restenosis 2006
    2006 Women and hypertension: What did we learn from the Women's Health Initiative? 2006
    2006 Phosphatidylinositol-3-kinase signaling mediates vascular smooth muscle cell expression of periostin in vivo and in vitro 2006
    2006 Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice 2006
    2006 Atrial natriuretic peptide-dependent modulation of hypoxia-induced pulmonary vascular remodeling 2006
    2006 Salt Sensitivity, a Determinant of Blood Pressure, Cardiovascular Disease and Survival 2006
    2006 Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival. 2006
    2006 Feasibility of treating prehypertension with an angiotensin-receptor blocker 2006
    2006 Pulsology rediscovered: Commentary on the Conduit Artery Function Evaluation (CAFE) study 2006
    2006 Dominant negative mutation of the TGF-β eceptor blocks hypoxia-induced pulmonary vascular remodeling 2006
    2006 American Society of Hypertension, Inc
Leadership Message 2006
    2006 Efficacy and Safety of Irbesartan/HCTZ Combination Therapy As Initial Treatment for Rapid Control of Severe Hypertension 2006
    2006 Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 2006
    2006 Metabolite ligands of estrogen receptor-β reduce primate coronary hyperreactivity 2006
    2006 Treatment of isolated systolic hypertension in diabetes mellitus type 2 2006
    2005 Hypertension 2005
    2005 Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers 2005
    2005 Estrogen treatment abrogates neointima formation in human C-reactive protein transgenic mice 2005
    2005 The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study 2005
    2005 Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling 2005
    2005 Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: The LIFE (Losartan Intervention for Endpoint reduction in hypertension) study 2005
    2005 Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy 2005
    2005 Fixed-dose combinations in the management of hypertension: Defining the place of angiotensin receptor antagonists and hydrochlorothiazide 2005
    2005 Conflicting and confusing data from the hypertension treatment trials: whom and what should you believe? 2005
    2005 Ethnicity and blood pressure. 2005
    2005 Gender and blood pressure. 2005
    2005 New-onset diabetes in treated hypertensive patients--is it clinically significant? Roundtable discussion. 2005
    2005 Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study 2005
    2005 Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals 2005
    2005 Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: The Losartan Intervention for Endpoint reduction in hypertension study 2005
    2005 The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. 2005
    2004 Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: The LIFE study 2004
    2004 Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling 2004
    2004 Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells 2004
    2004 Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries 2004
    2004 Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy 2004
    2004 Interview with Suzanne Oparil, MD. Interview by Marvin Moser, MD. 2004
    2004 Hypertensive therapy: Part I 2004
    2004 Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: The LIFE study 2004
    2004 Evidence-based guidelines for cardiovascular disease prevention in women 2004
    2004 Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. 2004
    2004 Summary of the American Heart Association's evidence-based guidelines for cardiovascular disease prevention in women. 2004
    2004 Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse 2004
    2004 Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women 2004
    2004 Estradiol and Progestins Differentially Modulate Leukocyte Infiltration after Vascular Injury 2004
    2004 Advanced glycation end-product cross-link breakers: A novel approach to cardiovascular pathologies related to the aging process 2004
    2004 Essential hypertension in women 2004
    2004 Hypertensive therapy: Part II. 2004
    2004 Roundtable discussion: blood pressure goal attainment: meeting the challenge of the JNC 7's blood pressure goals and the role of renin-angiotensin-aldosterone system blockade. 2004
    2004 The impact of serum uric acid on cardiovascular outcomes in the LIFE study 2004
    2003 Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study 2003
    2003 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 2003
    2003 Pathogenesis of Hypertension 2003
    2003 Hormone replacement therapy and inflammation: Interactions in cardiovascular disease 2003
    2003 Response to renin-angiotensin system antagonists in hypertensive black subjects [2] (multiple letters) 2003
    2003 Comparison of the SCOPE and LIFE results [2] (multiple letters) 2003
    2003 Comparison of the SCOPE and LIFE results. 2003
    2003 Effects of Losartan or Atenolol in Hypertensive Patients without Clinically Evident Vascular Disease: A Substudy of the LIFE Randomized Trial 2003
    2003 Fibroblast growth factor mediates hypoxia-induced endothelin-A receptor expression in lung artery smooth muscle cells 2003
    2003 Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse 2003
    2003 The seventh report of the joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC 7 report 2003
    2003 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report 2003
    2003 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Practical implications 2003
    2003 Pressure-independent enhancement of cardiac hypertrophy in atrial natriuretic peptide-deficient mice 2003
    2003 Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients 2003
    2003 α2A-adrenergic receptors mediate sympathoinhibitory responses to atrial natriuretic peptide in the mouse anterior hypothalamic nucleus 2003
    2003 Secondary prevention of coronary heart disease in women: A call to action 2003
    2003 Improving outcomes for women after coronary artery bypass grafting: A case for prevention 2003
    2003 Long-Term Safety and Efficacy of the Selective Aldosterone Blocker Eplerenone in Patients with Essential Hypertension 2003
    2003 The neointimal response ot endovascular injury is increased in obese Zucker rats 2003
    2002 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) 2002
    2002 Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT) 2002
    2002 Endothelin-A receptor blockade in porcine pulmonary hypertension 2002
    2002 Endothelin-A receptor blockade in porcine pulmonary hypertension. 2002
    2002 Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention For Endpoint reduction (LIFE) substudy 2002
    2002 Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study 2002
    2002 Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro 2002
    2002 Drugs targeting the renin-angiotensin-aldosterone system 2002
    2002 Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene 2002
    2002 Dietary salt supplementation selectively downregulates NPR-C receptor expression in kidney independently of ANP 2002
    2002 Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene. 2002
    2002 The effect of antihypertensive drugs on the fetus 2002
    2002 Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol 2002
    2002 Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol 2002
    2002 Hormone replacement therapy and hypertension 2002
    2002 Blood pressure and NaCl-sensitive hypertension are influenced by angiotensin-converting enzyme gene expression in transgenic mice 2002
    2002 Sex hormones and hypertension 2002
    2002 Blood pressure and NaCl-sensitive hypertension are influenced by angiotensin-converting enzyme gene expression in transgenic mice. 2002
    2002 Dietary salt supplementation selectively downregulates NPR-C receptor expression in kidney independently of ANP. 2002
    2002 Are there meaningful differences between antihypertensive agents? 2002
    2002 Are there meaningful differences in blood pressure control with current antihypertensive agents? 2002
    2002 Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists 2002
    2002 Do angiotensin receptor antagonists have benefits beyond blood pressure lowering? 2002
    2002 Interview: Suzanne Oparil, MD 2002
    2002 The effect of antihypertensive drugs on the fetus 2002
    2001 Erratum: Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension (Journal of Clinical Hypertension (2001) vol. 3(5) (283-291, 318)) 2001
    2001 Estrogen depletion induces NaCl-sensitive hypertension in female spontaneously hypertensive rats 2001
    2001 Estrogen depletion induces NaCl-sensitive hypertension in female spontaneously hypertensive rats. 2001
    2001 Estrogen-induced vasoprotection is independent of inducible nitric oxide synthase expression: Evidence from the mouse carotid artery ligation model 2001
    2001 Tyrosine kinase receptor activation inhibits NPR-C in lung arterial smooth muscle cells 2001
    2001 Efficacy of perindopril in the treatment of systemic hypertension. 2001
    2001 Efficacy of perindopril in the treatment of systemic hypertension 2001
    2001 The American journal of cardiology: Introduction 2001
    2001 Once-daily treatment of patients with hypertension: A placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone 2001
    2001 Tyrosine kinase receptor activation inhibits NPR-C in lung arterial smooth muscle cells. 2001
    2001 Cardiovascular effects of estrogen. 2001
    2001 Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension 2001
    2001 Genetic variation in angiotensin-converting enzyme does not prevent development of cardiac hypertrophy or upregulation of angiotensin II in response to aortocaval fistula 2001
    2001 Hormone replacement therapy and stroke: Are the results surprising? 2001
    2001 Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension 2001
    2001 Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs 2001
    2001 Health outcomes associated with calcium antagonists 2001
    2001 Hypertension. Introduction. 2001
    2001 Primary aldosteronism: A practical approach to diagnosis and treatment 2001
    2001 Treating hypertension in the elderly - Whom to treat, when, and with what? 2001
    2001 What do international guidelines say about therapy? 2001
    2000 Endothelin and pulmonary hypertension 2000
    2000 Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (Benazepril) with calcium antagonist (Either Nifedipine or Amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension 2000
    2000 Factors affecting blood pressure responses to diet: The vanguard study 2000
    2000 Calcium antagonists in cardiovascular disease: Clinical evidence from morbidity and mortality trials 2000
    2000 Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The life study 2000
    2000 Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. 2000
    2000 The organum vasculosum of the lamina terminalis regulates noradrenaline release in the anterior hypothalamic nucleus 2000
    2000 A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients impact on cardiovascular risk reduction 2000
    2000 Estrogen attenuates integrin-β3-dependent adventitial fibroblast migration after inhibition of osteopontin production in vascular smooth muscle cells 2000
    2000 Fenoldopam, a dopamine agonist, for hypertensive emergency: A multicenter randomized trial 2000
    2000 Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group. 2000
    2000 Estrogen-induced vasoprotection is estrogen receptor dependent: Evidence from the balloon-injured rat carotid artery model 2000
    2000 Effects of short-term estrogen treatment on the neointimal response to balloon injury of rat carotid artery 2000
    2000 Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries 2000
    2000 Essential hypertension part II: Treatment 2000
    2000 Essential hypertension. Part I: Definition and etiology 2000
    2000 Antihypertensive drug therapy in the third millennium: Are there benefits beyond blood pressure? 2000
    2000 Effects of increased consumption of fluid milk on energy and nutrient intake, body weight, and cardiovascular risk factors in healthy older adults 2000
    2000 Endothelial dysfunction in the pulmonary vascular bed 2000
    2000 Endothelin and pulmonary hypertension. 2000
    2000 Hypertension in women 2000
    2000 Newly emerging pharmacologic differences in angiotensin II receptor blockers 2000
    2000 Newly emerging pharmacologic differences in angiotensin II receptor blockers. 2000
    1999 Bradykinin in the heart: Friend or foe? 1999
    1999 Estrogen attenuates the adventitial contribution to neointima formation in injured rat carotid arteries 1999
    1999 Harriet Pearson Dustan. 1999
    1999 Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. 1999
    1999 Increased dietary micronutrients decrease serum homocysteine concentrations in patients at high risk of cardiovascular disease 1999
    1999 Treating multiple-risk hypertensive populations. 1999
    1999 Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro 1999
    1999 Effects of candesartan cilexetil in patients with severe systemic hypertension 1999
    1999 Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. 1999
    1999 Proposed changes for NIH's Center for Scientific Review. Panel on Scientific Boundaries for Review. Center for Scientific Review Advisory Committee, National Institutes of Health. 1999
    1999 Proposed changes for NIH's center for scientific review 1999
    1999 Fenoldopam: A new parenteral antihypertensive: Consensus roundtable on the management of perioperative hypertension and hypertensive crises 1999
    1999 Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo 1999
    1999 Guide to Preventive Cardiology for Women.AHA/ACC Scientific Statement Consensus panel statement. 1999
    1999 Guide to preventive cardiology for women 1999
    1999 AHA/ACC scientific statement: consensus panel statement. Guide to preventive cardiology for women. American Heart Association/American College of Cardiology. 1999
    1999 A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension 1999
    1999 A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. 1999
    1999 Journal of Cardiovascular Pharmacology: Introduction 1999
    1999 Long-term morbidity and mortality trials with amlodipine 1999
    1999 Management of the hypertensive patient with coronary artery disease. 1999
    1999 Multicenter randomized trial of a comprehensive prepared meal program in type 2 diabetes 1999
    1999 2-Tetradecylglycidic acid, an inhibitor of carnitine palmitoyltransferase-1, induces myocardial hypertrophy via the AT1 receptor 1999
    1999 Arthur C. Corcoran Memorial Lecture. Hormones and vasoprotection. 1999
    1999 Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. 1999
    1999 Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: Evaluation from a 12-week prospective, open-label clinical trial in community-based clinics 1999
    1999 Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women 1999
    1999 Comparison of telmisartan with lisinopril in patients with mild-to- moderate hypertension 1999
    1999 Dietary changes favorably affect bone remodeling in older adults 1999
    1999 Dietary salt reduction in hypertension - What is the evidence and why is it still controversial? 1999
    1999 Differential expression of angiotensin-converting enzyme and chymase in dogs with chronic mitral regurgitation 1999
    1999 Differential expression of natriuretic peptides and their receptors in volume overload cardiac hypertrophy in the rat 1999
    1999 Eprosartan versus enalapril in hypertensive patients with angiotensin- converting enzyme inhibitor-induced cough 1999
    1999 Guide to preventive cardiology for women 1999
    1999 Hypertension in women 1999
    1999 Management of the hypertensive patient with coronary artery disease 1999
    1999 Nontraditional cardiovascular risk factors 1999
    1999 Nutritionally complete prepared meal plan to reduce cardiovascular risk factors: A randomized clinical trial 1999
    1999 Recent outcome trials of newer antihypertensives 1999
    1999 Treating multiple-risk hypertensive populations 1999
    1998 Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. 1998
    1998 Healthier diets improve quality of life while reducing cardiovascular disease risk factors 1998
    1998 Case study 1998
    1998 The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study. 1998
    1998 Effects of Candesartan cilexetil in patients with systemic hypertension 1998
    1998 Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. 1998
    1998 Garlic prevents hypoxic pulmonary hypertension in rats 1998
    1998 Garlic prevents hypoxic pulmonary hypertension in rats. 1998
    1998 Pathophysiology of sudden coronary death in women: Implications for prevention 1998
    1998 An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. 1998
    1998 Antihypertensive treatment in postmenopausal women: Results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (Moexipril) with a diuretic (Hydrochlorothiazide) 1998
    1998 Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension. 1998
    1998 Managing the patient with hard-to-control hypertension 1998
    1998 An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan 1998
    1998 Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE study 1998
    1998 Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension 1998
    1998 Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension. 1998
    1998 Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker 1998
    1998 Mibefradil, a T-channel-selective calcium antagonist: Clinical trials in hypertension 1998
    1998 The sexual dimorphism of high blood pressure 1998
    1997 No role for NO in estrogen-mediated vasoprotection? 1997
    1997 High blood pressure in women 1997
    1997 Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations 1997
    1997 Hypoxia stimulates human preproendothelin-1 promoter activity in transgenic mice 1997
    1997 Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. 1997
    1997 Hypoxia stimulates human preproendothelin-1 promoter activity in transgenic mice. 1997
    1997 Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs 1997
    1997 Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs 1997
    1997 A 42-year-old man with hypertension 1997
    1997 Estrogen restores endothelial cell function in an experimental model of vascular injury 1997
    1997 Antihypertensive effects of mibefradil in the treatment of mild-to- moderate systemic hypertension 1997
    1997 Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension. 1997
    1997 Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension 1997
    1997 Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. 1997
    1997 Compartmentalization of angiotensin II generation in the dog heart: Evidence for independent mechanisms in intravascular and interstitial spaces 1997
    1997 Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin-converting enzyme gene function. 1997
    1997 Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. 1997
    1997 The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. 1997
    1997 The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats 1997
    1997 Scientists' statement regarding data on the sodium-hypertension relationship and sodium health claims on food labeling 1997
    1997 Nutritional management of cardiovascular risk factors: A randomized clinical trial 1997
    1997 ALLHAT and calcium channel blockers [3] 1997
    1997 ALLHAT and calcium channel blockers. ALLHAT Research Group. 1997
    1997 Blood pressure and metabolic responses to moderate sodium restriction in isradipine-treated hypertensive patients 1997
    1997 Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin-converting enzyme gene function 1997
    1997 Dietary compliance and cardiovascular risk reduction with a prepared meal plan compared with a self-selected diet 1997
    1997 Erratum: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension (American Journal of Hypertension (July 1997) 10 (735-742)) 1997
    1997 Fenoldopam: A novel, peripherally acting dopamine-1 agonist for parenteral treatment of hypertension 1997
    1997 Gender and cardiovascular disease: Recent insights 1997
    1997 Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment 1997
    1997 The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study rationale, design, and methods 1997
    1997 The expanding role of calcium antagonists in cardiovascular disease 1997
    1997 Tolerability profile of tasosartan, a long-acting angiotensin II AT1 receptor blocker, in the treatment of patients with essential hypertension 1997
    1996 Hypoxia decreases atrial natriuretic peptide clearance receptor (ANP-CR) gene expression in peripheral organs, but not in the brain, of rats 1996
    1996 Hypoxia stimulates human preproendothelin-1 (PPET-1) promoter activity in transgenic mice 1996
    1996 Identification of the hypoxia-responsive element in the 5′ flanking region of human endothelin-1 gene 1996
    1996 Selective enhancement of angiotensin converting enzyme (ACE) gene expression in the heart during the development and maintenance of pressure overload cardiac hypertrophy 1996
    1996 Tbc11251, a highly selective endothelin-a receptor antagonist. prevents and reverses acute hypoxia-fnduced pulmonary hypertension in the rat 1996
    1996 Atrial natriuretic peptide regulation of noradrenaline release in the anterior hypothalamic area of spontaneously hypertensive rats 1996
    1996 Purification and assay methods for angiotensin-converting enzyme 1996
    1996 Preventing heart attack and death in patients with coronary disease. Endorsed by the board of trustees of the American College of Cardiology. 1996
    1996 Antihypertensive therapy in the era of evidence based medical practice: What to do until the facts are in 1996
    1996 Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. 1996
    1996 Acute saline infusion decreases norepinephrine release in the anterior hypothalamic area. 1996
    1996 Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery 1996
    1996 17-β estradiol but not medroxyprogesterone inhibits neointima formation after balloon injury of rat carotid arteries 1996
    1996 17-β estradiol inhibits restenosis after coronary angioplasty in pigs 1996
    1996 A-127722, an orally active antagonist of the endothelin-a receptor, retards the progression of chronic hypoxia induced pulmonary hypertension in the rat 1996
    1996 Anterior hypothalamic norepinephrine, atrial natriuretic peptide, and hypertension 1996
    1996 Antihypertensive therapy and atherosclerosis in coronary heart disease 1996
    1996 Atrial natriuretic peptide blunts arterial baroreflex in spontaneously hypertensive rats 1996
    1996 Cardiac renin angiotensin system in hypertrophy and the progression to heart failure 1996
    1996 Cardiovascular risk reduction in women 1996
    1996 Classic papers symposium of the southern clinical research meetings: White coat hypertension - Fact or fancy? 1996
    1996 Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension 1996
    1996 Estrogen, but not androgen, inhibits the proliferation of cultured vascular smooth muscle cells derived from male and female spontaneously hypertensive rats 1996
    1996 Hypertension: Initial evaluation 1996
    1996 Hypoxia decreases atrial natriuretic peptide clearance receptor gene expression in pulmonary vascular smooth muscle cells in situ 1996
    1996 Hypoxia enhances promoter activity of human endothelin-1 gene in transgenic mice 1996
    1996 Improved quality of life in patients with generalized cardiovascular metabolic disease on a prepared diet 1996
    1996 Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery 1996
    1996 Ovariectomy induces NaCl-sensitivity in female spontaneously hypertensive rats 1996
    1996 Phenotypic characterization of transgenic mice with "knockout" for the angiotensin converting enzyme 1996
    1996 Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) 1996
    1996 Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension 1996
    1996 The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension 1996
    1995 Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation 1995
    1995 Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. 1995
    1995 ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. 1995
    1995 Sensitive method for quantitation of angiotensin-converting enzyme (ACE) activity in tissue 1995
    1995 Hypertension in postmenopausal women: Pathophysiology and management 1995
    1995 Calcium antagonists: Antihypertensive and vascular considerations 1995
    1995 Hypertensive crisis since fdr – a partial victory 1995
    1995 Acute hypertension increases norepinephrine release in the anterior hypothalamic area. 1995
    1995 Cardiovascular health at the crossroads: outlook for the 21st century. Presented at the 67th Scientific Sessions of the American Heart Association November 4, 1994 Dallas, Texas. 1995
    1995 Selective downregulation of ANP-clearance-receptor gene expression in lung of rats adapted to hypoxia. 1995
    1995 ET(A)-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat 1995
    1995 Effect of amlodipine on left ventricular mass in the amlodipine cardiovascular community trial 1995
    1995 Effects of dietary salt on angiotensin peptides in kidney 1995
    1995 Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat 1995
    1995 Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat. 1995
    1995 Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats 1995
    1995 Fighting the NIH funding crisis 1995
    1995 Gender and dietary NaCl in spontaneously hypertensive and Wistar-Kyoto rats 1995
    1995 Initial medication selection for treatment of high blood pressure 1995
    1995 Preventing heart attack and death in patients with coronary disease 1995
    1995 Racial differences in the pathogenesis of hypertension 1995
    1995 SSCI founders medal recipient's address 1995
    1995 Selective downregulation of ANP-clearance-receptor gene expression in lung of rats adapted to hypoxia 1995
    1995 The Elusive Role of Atrial Natriuretic Peptide in Hypertension 1995
    1994 Increased endothelin receptor gene expression in hypoxic rat lung. 1994
    1994 Antihypertensive therapy in the context of total cardiovascular risk: the rational basis for therapeutic recommendations. 1994
    1994 Diurnal blood pressure variation and dietary salt in spontaneously hypertensive rats 1994
    1994 Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia 1994
    1994 Increased endothelin receptor gene expression in hypoxic rat lung 1994
    1994 Increased endothelin receptor gene expression in hypoxic rat lung 1994
    1994 Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo 1994
    1994 Muscle sympathetic nervous system activity in black and caucasian hypertensive subjects 1994
    1994 Role of anterior hypothalamic angiotensin II in the pathogenesis of salt sensitive hypertension in the spontaneously hypertensive rat 1994
    1994 Sodium-proton (Na+/H+) exchange inhibition increases blood pressure in spontaneously hypertensive rat 1994
    1994 The role of atrial natriuretic peptide and endothelin in hypoxia induced pulmonary hypertension. 1994
    1993 Report of the task force on children and youth. American Heart Association. 1993
    1993 Simplified method for quantitation of angiotensin peptides in tissue 1993
    1993 Antihypertensive Therapy – Efficacy and Quality of Life 1993
    1993 Coarctation induces alterations in basement membranes in the cardiovascular system 1993
    1993 Excitatory sympathetic reflex in NaCl-sensitive spontaneously hypertensive rats 1993
    1993 Nitric oxide mediates immune dysfunction in the spontaneously hypertensive rat 1993
    1993 Normotensive blacks have heightened sympathetic response to cold pressor test 1993
    1993 Presentation of the Southern Society for Clinical Investigation Founder's Medal to Dr. James A. Pittman, Jr. 1993
    1993 Report of the task force on children and youth 1993
    1992 Normobaric hypoxia stimulates endothelin-1 gene expression in the rat 1992
    1992 Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. 1992
    1992 Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cells. 1992
    1992 Preparative isolation of angiotensin-converting enzyme from human lung 1992
    1992 Isolation of two distinct type I angiotensin II receptor genes 1992
    1992 Effects of acute and chronic blockade of neutral endopeptidase with Sch 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats. 1992
    1992 Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats 1992
    1992 Atrial natriuretic peptide modulates baroreceptor reflex in spontaneously hypertensive rat 1992
    1992 Blocking hypothalamic AT1 receptors lowers blood pressure in salt- sensitive rats 1992
    1992 Cicletanine blunts the pulmonary pressor response to acute hypoxia in rats 1992
    1992 Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cells 1992
    1992 Depressor effect of blocking angiotensin subtype 1 receptors in anterior hypothalamus 1992
    1992 Effects of acute and chronic blockade of neutral endopeptidase with sch 34826 on nacl-sensitive hypertension in spontaneously hypertensive rats 1992
    1992 Ganglion atrial natriuretic peptide in nacl sensitive spontaneously hypertensive rats 1992
    1992 Neuronal control of the kidney: Contribution to hypertension 1992
    1992 Preparative isolation of angiotensin-converting enzyme from human lung 1992
    1992 Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii 1992
    1992 Quantitation of hypothalamic atrial natriuretic peptide messenger RNA in hypertensive rats 1992
    1992 Salt supplementation does not alter the pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii 1992
    1992 Sex difference in blood pressure of spontaneously hypertensive rats influenced by perinatal NaCl exposure 1992
    1992 Spontaneously hypertensive rat: Lymphoid depression is age dependent and mediated via a mononuclear cell subpopulation 1992
    1992 Spontaneously hypertensive rat: lymphoid depression is age dependent and mediated via a mononuclear cell subpopulation. 1992
    1991 Decreased norepinephrine release in anterior hypothalamus of NaCl-sensitive spontaneously hypertensive rats during high NaCl intake 1991
    1991 Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats via sympatholytic and renal effects 1991
    1991 Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats via sympatholytic and renal effects. 1991
    1991 The calcium antagonists in the 1990s. An overview. 1991
    1991 Altered stores of atrial natriuretic peptide in specific brain nuclei of NaCl-sensitive spontaneously hypertensive rats. 1991
    1991 Treatment of hypertensive crisis 1991
    1991 Altered stores of atrial natriuretic peptide in specific brain nuclei of nacl-sensitive spontaneously hypertensive rats 1991
    1991 Antihypertensive effect of cicletanine is exaggerated in NaCl-sensitive hypertension 1991
    1991 Atrial natriuretic peptide in acute hypoxia-induced pulmonary hypertension in rats 1991
    1991 Atrial natriuretic peptide inhibits sympathetic outflow in NaCi-sensitive spontaneously hypertensive rats 1991
    1991 High NaCl diet enhances arterial baroreceptor reflex in NaCl-sensitive spontaneously hypertensive rats 1991
    1991 Intrahypothalamic clonidine infusion prevents NaCl-sensitive hypertension 1991
    1991 Neuronal angiotensin-converting enzyme (ACE) gene expression is increased by converting enzyme inhibitors (CEI) 1991
    1991 The calcium antagonists in the 1990s an overview 1991
    1990 Treatment of hypertensive crisis 1990
    1990 In Reply 1990
    1990 Dietary Ca2+ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism. 1990
    1990 High-performance liquid chromatographic determination of amiloride and its analogues in rat plasma. 1990
    1990 An Assessment of Diltiazem and Hydrochlorothiazide in Hypertension: Application of Factorial Trial Design to a Multicenter Clinical Trial of Combination Therapy 1990
    1990 Vascular effects of kinins in trout and bradykinin metabolism by perfused gill. 1990
    1990 Atrial natriuretic factor prevents NaCl-sensitive hypertension in spontaneously hypertensive rats 1990
    1990 Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia 1990
    1990 Atrial natriuretic peptide clearance receptor agonist lowers pulmonary pressure in hypoxic rats 1990
    1990 Blockade of endogenous anterior hypothalamic atrial natriuretic peptide with monoclonal antibody lowers blood pressure in spontaneously hypertensive rats 1990
    1990 Changes in cerebrospinal fluid Na+ concentration do not underlie hypertensive responses to dietary NaCl in spontaneously hypertensive rats 1990
    1990 Dietary ca2+ increases natriuretic and diuretic responses to volume loading in nacl-sensitive spontaneously hypertensive rats 1990
    1990 Dietary ca2+prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism 1990
    1990 High-performance liquid chromatographic determination of amiloride and its analogues in rat plasma 1990
    1990 Interleukin-2 does not attenuate hypertension in spontaneously hypertensive rats 1990
    1990 Lesions of the anterior hypothalamic area increase arterial pressure in NaCl-sensitive spontaneously hypertensive rats 1990
    1990 NaCl does not affect hypothalamic noradrenergic input in deoxycorticosterone acetate/NaCl and dahl salt-sensitive rats 1990
    1990 Noninvasive Assessment of Renal Artery Stenosis by Combined Conventional and Color Doppler Ultrasound 1990
    1990 Vascular effects of kinins in trout and bradykinin metabolism by perfused gill 1990
    1989 Central mechanisms of hypertension. 1989
    1989 Dietary NaCl loading enhances antihypertensive effect of guanabenz in spontaneously hypertensive rats. 1989
    1989 Hypoxia stimulates endothelial cell angiotensin-converting enzyme antigen synthesis. 1989
    1989 A simple method for concentration of biogenic amines and their metabolites from biological samples for analysis by HPLC-EC 1989
    1989 Atrial natriuretic factor in NaCl-sensitive and NaCl-resistant spontaneously hypertensive rats 1989
    1989 Atrial natriuretic peptide lowers pulmonary arterial pressure in patients with high altitude disease 1989
    1989 Central mechanisms of hypertension 1989
    1989 Dietary Ca2+ supplementation prevents the exaggerated responsiveness of anterior hypothalamic α2-adrenoceptors in NaCl-loaded spontaneously hypertensive rats 1989
    1989 Dietary ca<sup>2+</sup> prevents naci-induced exacerbation of hypertension and increases hypothalamic norepinephrine turnover in spontaneously hypertensive rats 1989
    1989 Hemodynamic effects of arginine vasopressin in rats adapted to chronic hypoxia 1989
    1989 Hypertension 1989
    1989 Hypoxia stimulates endothelial cell angiotensin-converting enzyme antigen synthesis 1989
    1989 Impaired reflex response to volume expansion in NaCl-sensitive spontaneously hypertensive rats 1989
    1989 Purification of angiotensin-converting enzyme by gel high-performance liquid chromatography 1989
    1989 Renal nerve contribution to NaCl-exacerbated hypertension in spontaneously hypertensive rats 1989
    1989 Vasopressin lowers pulmonary artery pressure in hypoxic rats by releasing atrial natriuretic peptide 1989
    1988 Enhanced cold pressor response in spontaneously hypertensive rats on high-NaCl diet 1988
    1988 Lung MK 351A uptake after hypoxia adaptation and subsequent hyperoxia exposure 1988
    1988 Enhanced cold pressor response in spontaneously hypertensive rats on high-NaCl diet. 1988
    1988 Treating the older hypertensive patient-an overview 1988
    1988 Effect of steric exclusion on the separation of proteins by hydrophilic size-exclusion chromatography. 1988
    1988 Exaggerated depressor response to 6-iodoamiloride in NaCl-sensitive spontaneously hypertensive rats. 1988
    1988 High NaCl diet increases anterior hypothalamic α2-adrenoceptors in SHR 1988
    1988 Impaired release of atrial natriuretic factor in NaCl-loaded spontaneously hypertensive rats. 1988
    1988 Captopril and the response to stress in the spontaneously hypertensive rat. 1988
    1988 Altered angiotensin-converting enzyme in lung and extrapulmonary tissues of hypoxia-adapted rats 1988
    1988 Atrial natriuretic peptide lowers pulmonary arterial pressure in hypoxia-adapted rats 1988
    1988 Captopril and the response to stress in the spontaneously hypertensive rat 1988
    1988 Central serotonergic alterations in deoxycorticosterone acetate/NaCl (DOCA/NaCl)-induced hypertension 1988
    1988 Chronic infusion of atrial natriuretic peptide prevents pulmonary hypertension in hypoxia-adapted rats. 1988
    1988 Current and future role of catapresan in the treatment of hypertension 1988
    1988 Effect of steric exclusion on the separation of proteins by hydrophilic size-exclusion chromatography 1988
    1988 Genetic basis of NaCl-sensitive hypertension 1988
    1988 High NaCl diet reduces hypothalamic norepinephrine turnover in hypertensive rats 1988
    1988 Hypothalamic microinjection of alpha<inf>2</inf>-adrenoceptor agonists causes greater sympathoinhibition in spontaneously hypertensive rats on high NaCl diets 1988
    1988 Hypoxia-induced oxygen tolerance: Maintenance of endothelial metabolic function 1988
    1988 Impaired release of atrial natriuretic factor in NaCl-loaded spontaneously hypertensive rats 1988
    1988 Lung MK 351A uptake after hypoxia adaptation and subsequent hyperoxia exposure. 1988
    1988 Perioperative red blood cell transfusion 1988
    1988 Purification of an angiotensin II binding protein by using antibodies to a peptide encoded by angiotensin II complementary RNA 1988
    1988 Rapid communication: Exaggerated depressor response to 6-iodoamiloride in NaCl-sensitive spontaneously hypertensive rats 1988
    1988 The neural basis of salt sensitivity in the rat: Altered hypothalamic function 1988
    1988 The use of complementary peptides in the purification of an angiotensin II binding protein 1988
    1987 Role of vasopressin in the cardiovascular effects of LY171555, a selective dopamine D2 receptor agonist: Studies in conscious Brattleboro and Long-Evans rats 1987
    1987 Role of the dissolution mechanism in determining chromatographic separation of biogenic amines from their precursors and metabolites by HPLC-EC 1987
    1987 Altered responsiveness of regional brain dopamine and DOPAC levels to systemic administration of quinpirole, a dopamine D2 agonist, in DOCA/NaCl-hypertensive rats 1987
    1987 De novo intrarenal formation of angiotensin II during control and enhanced renin secretion. 1987
    1987 Exacerbation of hypertension by high chloride, moderate sodium diet in the salt-sensitive spontaneously hypertensive rat. 1987
    1987 Sympathetic function in spontaneously hypertensive rats after chronic administration of captopril. 1987
    1987 Two renal alpha 2-adrenergic receptor sites revealed by p-aminoclonidine binding. 1987
    1987 Enhanced response to the inhibitory action of LY171555, a dopamine D2-agonist, on in vivo striatal dopamine release in DOCA/NaCl-hypertensive rats 1987
    1987 Antihypertensive effect of enalapril in essential hypertension: Role of prostacyclin 1987
    1987 Blunted responsiveness of posterior hypothalamic norepinephrine to quinpirole in DOCA/NaCl hypertensive rats 1987
    1987 Continuous intravenous infusion of LY171555, a potent selective D<inf>2</inf> receptor agonist, lowers blood pressure in the conscious rat 1987
    1987 De novo intrarenal formation of angiotensin II during control and enhanced renin secretion 1987
    1987 Exacerbation of hypertension by high chloride, moderate sodium diet in the salt-sensitive spontaneously hypertensive rat 1987
    1987 Failure of renal denervation to attenuate hypertension in Dahl NaCl-sensitive rats 1987
    1987 Hyperoxia-induced converting enzyme insufficiency in conscious rat: Cardiovascular effects 1987
    1987 Hypertension produced by a high sodium diet in the borderline hypertensive rat (BHR) 1987
    1987 Hypertension produced by a high sodium diet in the borderline hypertensive rat (BHR). 1987
    1987 Hypoxia-induced inhibition of converting enzyme activity: Role in vascular regulation 1987
    1987 Proteoglycans and hypertension: III: Aorta proteoglycans in Dahl salt-sensitive hypertensive rats 1987
    1987 Renal catecholamines and α2-adrenergic receptors in salt-related and genetic hypertension 1987
    1987 Spontaneously hypertensive rats exhibit reduced hypothalamic noradrenergic input after NaCl loading 1987
    1987 Sympathetic function in spontaneously hypertensive rats after chronic administration of captopril 1987
    1987 The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension 1987
    1987 The renal afferent nerves in the pathogenesis of hypertension 1987
    1987 Two renal α2-adrenergic receptor sites revealed by p-aminoclonidine binding 1987
    1987 Yohimbine-induced alterations of monoamine metabolism in the spontaneously hypertensive rat of the okamoto strain (SHR). II. The Central Nervous System (CNS) 1987
    1987 Yohimbine-induced alterations of monoamine metabolism in the spontaneously hypertensive rat. I. The peripheral nervous system 1987
    1986 Mechanism of the depressor action of LY171555, a selective dopamine D2 receptor agonist, in the anesthetized rat 1986
    1986 Transport and hydrolysis of glucagon in the proximal nephron 1986
    1986 Transport and hydrolysis of glucagon in the proximal nephron. 1986
    1986 Angiotensin extraction by trout tissues in vivo and metabolism by the perfused gill. 1986
    1986 Angiotensin extraction by trout tissues in vivo and metabolism by the perfused gill 1986
    1986 Effects of locally formed angiotensin II on renal hemodynamics 1986
    1986 Genetic and salt-related alterations in monoamine neurotransmitters in dahl salt-sensitive and salt-resistant rats 1986
    1986 Impaired pulmonary conversion of angiotensin I to angiotensin II in rats exposed to chronic hypoxia 1986
    1986 Increased vasopressinergic activity following DOCA administration in the rat 1986
    1986 Mechanism of the pressor action of LY171555, a specific dopamine D2 receptor agonist, in the conscious rat 1986
    1986 Proteoglycans and Hypertension I.A Biochemical and Ultrastructural Study of Aorta Glycosaminoglycans in Spontaneously Hypertensive Rats 1986
    1986 Sensory denervation of the kidney attenuates renovascular hypertension in the rat 1986
    1986 Sensory denervation of the kidney attenuates renovascular hypertension in the rat. 1986
    1986 The sympathetic nervous system in clinical and experimental hypertension 1986
    1985 Enhanced depressor effect of bromocriptine in the DOCA/NaCl hypertensive rat 1985
    1985 Hyperresponsiveness of monoaminergic mechanisms in DOCA/NaCl hypertensive rats 1985
    1985 Hypertension in a 74-year-old man with hydronephrosis and coronary disease. 1985
    1985 Enhanced depressor effect of bromocriptine in the DOCA/NaCl hypertensive rat. 1985
    1985 Hyperresponsiveness of monoaminergic mechanisms in DOCA/NaCl hypertensive rats. 1985
    1985 Pathogenesis of ventricular hypertrophy. 1985
    1985 Enhanced Depressor Effect of Muscimol in the DOCA/NaCl Hypertensive Rat: Evidence for Altered GABAergic Activity in Brain 1985
    1985 Hypertension in a 74-year-old man with hydronephrosis and coronary disease principal discussant 1985
    1985 Metabolism of angiotensin I by the trout gill 1985
    1985 Morphologie substrates of sudden death: Questions and answers 1985
    1985 Pathogenesis of ventricular hypertrophy 1985
    1985 Reverse-phase separation and electrochemical detection of neuropeptides 1985
    1984 The role of the posterior hypothalamic area in the pathogenesis of hypertension in the spontaneously hypertensive rat 1984
    1984 Effect of central administration of MK-422 (the diacid form of enalapril) on the development of hypertension in the spontaneously hypertensive rat 1984
    1984 Effect of central administration of MK-422 (the diacid form of enalapril) on the development of hypertension in the spontaneously hypertensive rat. 1984
    1984 Myocardial cell hypertrophy or hyperplasia 1984
    1984 Renal handling of glucagon and insulin. 1984
    1984 Myocardial cell hypertrophy or hyperplasia. 1984
    1984 Hormonal and haemodynamic responses to upper abdominal surgery during isoflurane and balanced anaesthesia 1984
    1984 Renovascular hypertension in middle-aged females. 1984
    1984 Subcellular sites of insulin hydrolysis in renal proximal tubules 1984
    1984 Elevated catecholamines during cardiac surgery: Consequences of reperfusion of the postarrested heart 1984
    1984 A randomized comparison of crystalloid and blood-containing cardioplegic solutions in 60 patients 1984
    1984 Basal release of striatal dopamine is higher in spontaneously hypertensive rats than in Wistar Kyoto controls 1984
    1984 Blood pressure oscillations in postsurgical hypertension during automatic control 1984
    1984 Comprehensive drug management of hypertension 1984
    1984 Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat 1984
    1984 Myocardial cell hypertrophy or hyperplasia 1984
    1984 Renal handling of glucagon 1984
    1984 Subcellular sites of insulin hydrolysis in renal proximal tubules 1984
    1983 Effect of hypoxia on the conversion of angiotensin I to II in cultured porcine pulmonary endothelial cells 1983
    1983 Altered vascular reactivity and baroreflex sensitivity induced by chronic central administration of captopril in the spontaneously hypertensive rat 1983
    1983 Attenuation of the development of spontaneous hypertension in rats by chronic central administration of captopril 1983
    1983 Central catecholamine depletion, vasopressin, and blood pressure in the DOCA/NaCl rat 1983
    1983 Central catecholamine depletion, vasopressin, and blood pressure in the DOCA/NaCl rat 1983
    1983 Enalapril in low-renin essential hypertension 1983
    1983 Immunoreactive bradykinin and [des-Arg9]-bradykinin in low-renin essential hypertension-before and after treatment with enalapril (MK421) 1983
    1983 Intrarenal angiotensin I conversion at normal and reduced renal blood flow in the dog 1983
    1983 Kidney function and sodium handling in the pregnant spontaneously hypertensive rat 1983
    1983 Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat (SHR) 1983
    1983 Role of the renal nerves in the maintenance of DOCA-salt hypertension in the rat. Influence on the renal vasculature and sodium excretion 1983
    1982 Differences between renal tubular processing of glucagon and insulin 1982
    1982 Importance of the renal nerves in the pathogenesis of experimental hypertension. 1982
    1982 The AFCR: is there life after 41? 1982
    1982 Importance of the renal nerves in established two-kidney, one clip Goldblatt hypertension. 1982
    1982 Effect of hypoxia on the conversion of angiotensin I to II in the isolated perfused rat lung 1982
    1982 1982: A critical year for hypertension 1982
    1982 Angiotensin-converting enzyme in serum and in bronchoalveolar lavage in sarcoidosis 1982
    1982 Central effects of prostaglandin E2 on blood pressure and plasma renin activity in rats role of the sympathoadrenal system and vasopressin 1982
    1982 Central sympathectomy with 6-hydroxydopamine prevents DOCA/NaCl hypertension by mechanisms independent of vasopressin 1982
    1982 Decrease in hypothalamic norepinephrine content following renal denervation in the one-kidney, one clip goldblatt hypertensive rat 1982
    1982 Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat 1982
    1982 Decrease in sympathetic nervous system activity and attenuation in response to stress following renal denervation in the one-kidney one-clip Goldblatt hypertensive rat. 1982
    1982 Decrease in sympathetic nervous system activity and attenuation in response to stress following renal denervation in the one-kidney one-clip goldblatt hypertensive rat 1982
    1982 Differences between renal tubular processing of glucagon and insulin 1982
    1982 Gallium 67 citrate scanning and serum angiotensin converting enzyme levels in sarcoidosis 1982
    1982 Importance of the renal Nerves in the Pathogenesis of Experimental Hypertension 1982
    1982 Importance of the renal nerves in established Two-Kidney, one clip goldblatt hypertension 1982
    1982 Increased noradrenaline content of hypothalamic nuclei in association with worsening of hypertension after high sodium intake in the young spontaneously hypertensive rat 1982
    1982 Increased noradrenergic activity in hypothalamic nuclei of spontaneously hypertensive rats on high sodium intake 1982
    1982 Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man 1982
    1982 Prevention of hypertension in the spontaneously hypertensive rat by chronic central administration of captopril 1982
    1982 Review of therapeutic modalities acting directly via central pathways 1982
    1982 Review of therapeutic modalities acting directly via central pathways. 1982
    1982 Sodium-neural interactions in the development of spontaneous hypertension 1982
    1982 Sodium-neural interactions in the development of spontaneous hypertension. 1982
    1982 The role of calcium in the control of renin release 1982
    1981 A progress report on hypertension 1981
    1981 Angiotensin II metabolism by tissues from developing rats 1981
    1981 Catecholamine changes during cardiopulmonary bypass: The stress response and role of the lungs in modulating it 1981
    1981 Central effects of prostaglandin E2 on blood pressure and plasma renin activity: Role of the sympathoadrenal system and vasopressin 1981
    1981 Decreased serum angiotensin converting enzyme in adult respiratory distress syndrome associated with sepsis: a preliminary report. 1981
    1981 Effects of sodium intake and Goldblatt hypertension on renin release in rat kidney slices 1981
    1981 Effects of sodium intake and Goldblatt hypertension on renin release in rat kidney slices 1981
    1981 Hypertension and oral contraceptives 1981
    1981 Lofexidine and clonidine in moderate essential hypertension 1981
    1981 Prevention of DOCA/NaCl hypertension in the rat by central sympatholytic treatment is unrelated to vasopressin 1981
    1981 Renal function during reflexly activated catecholamine flow through an adrenorenal rete 1981
    1981 Renal function during reflexly activated catecholamine flow through an adrenorenal rete 1981
    1981 Role of the Renal Nerves in the Pathogenesis of One-Kidney Renal Hypertension in the Rat 1981
    1980 Diurnal patterns and regulation of cortisol secretion in pregnancy 1980
    1980 Drug management of hypertension 1980
    1980 Effect of acute hypoxia on the pulmonary conversion of angiotensin I to angiotensin II in dogs 1980
    1980 Effect of molecular size and structure on renal tubular processing of peptides 1980
    1980 Hemodynamic Response to Vascular Expansion Following Immunosympathectomy in Spontaneously Hypertensive Rats 1980
    1980 Importance of Renal Sympathetic Tone in the Development of DOCA-Salt Hypertension in the Rat 1980
    1980 Lofexidine in essential hypertension: Double blind comparison with clonidine 1980
    1980 Multiclinic double-blind evaluation of timolol combined with hydrochlorothiazide in essential hypertension 1980
    1980 NMR observation of altered sodium interaction with human erythrocyte membranes of essential hypertensives 1980
    1980 Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: A study of hemodynamic and humoral factors 1980
    1980 Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat 1980
    1980 The first year of hypertension 1980
    1979 Hypertrophy in the denervated heart: A comparison of central sympatholytic treatment with 6-hydroxydopamine and peripheral sympathectomy with nerve growth factor antiserum 1979
    1979 A simple method for determining the free cortisol index in plasma: measurements in human pregnancy 1979
    1979 Clinical significance of serum angiotensin-converting enzyme levels in sarcoidosis 1979
    1979 Desoxycorticosterone in normal pregnancy. II. Cortisol-dependent fluctuations in free plasma desoxycorticosterone 1979
    1979 Effect of acute hypoxia on in-vivo conversion of angiotensin I to II in dogs 1979
    1979 Hypertension: A new journal 1979
    1979 Mechanism for renal tubular handling of angiotensin 1979
    1979 Mechanism for renal tubular handling of angiotensin 1979
    1979 Mechanism of angiotensin i converting enzyme inhibition by SQ20,881 (<Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) in vivo: Further evidence for extrapulmonary conversion 1979
    1979 Mechanism of postarrhythmic renal vasoconstriction in the anesthetized dog 1979
    1979 Nomenclature for experimental renovascular hypertension. Report of the Nomenclature Committee of the Council for High Blood Pressure Research of the American Heart Association. 1979
    1979 Regional myocyte size in normotensive and spontaneously hypertensive rats 1979
    1979 Renal tubular handling of glucagon and insulin 1979
    1979 Renal tubular transport and catabolism of proteins and peptides 1979
    1979 The effect of renal denervation on the development of DOCA-salt hypertension in the rat 1979
    1978 Desoxycorticosterone in normal pregnancy. I. Sequential studies of the secretory patterns of desoxycorticosterone, aldosterone, and cortisol 1978
    1978 Inhibition of renin release from rat kidney slices by the angiotensins. 1978
    1978 Effects of constituent amino acids on tubular handling of microinfused angiotensin II. 1978
    1978 Effect of peripheral sympathectomy on left ventricular ultrastructure in young spontaneously hypertensive rats. 1978
    1978 Calcium dependence of angiotensin II induced inhibition of renin release in vitro 1978
    1978 Effect of peripheral sympathectomy on left ventricular ultrastructure in young spontaneously hypertensive rats 1978
    1978 Effects of constituent amino acids on tubular handling of microinfused angiotensin II 1978
    1978 In vivo and in vitro conversion of des-1-Asp angiotensin I to angiotensin III 1978
    1978 Inhibition of renin release from rat kidney slices by the angiotensin 1978
    1978 Myocardial hypertrophy and ventricular performance in the absence of hypertension in spontaneously hypertensive rats 1978
    1978 Plasma angiotensin converting enzyme activity in mother and fetus 1978
    1978 Report of the AFCR public policy committee: current legislative priorities 1978
    1978 Report of the AFCR public policy committee: current legislative priorities 1978
    1978 The mechanism of post-arrhythmic renal vasoconstriction in the dog 1978
    1977 Handling of angiotensin II and oxytocin by renal tubular segments perfused in vitro 1977
    1977 Sodium and mineralocorticoids in normal and abnormal pregnancy. 1977
    1977 Changing patterns of corticoid responses to ACTH during normal pregnancy 1977
    1977 Development of left ventricular hypertrophy in young spontaneously hypertensive rats after peripheral sympathectomy 1977
    1977 Drug treatment of hypertension 1977
    1977 Handling of angiotensin II and oxytocin by renal tubular segments perfused in vitro 1977
    1977 Relation of renal hemodynamics to metabolism of angiotensin II by the canine kidney 1977
    1977 Treatment of hypertension by computer and physician-A prospective controlled study 1977
    1976 Altered angiotensin I conversion in pulmonary disease 1976
    1976 Catecholamines, blood pressure, renin and myocardial function in the spontaneously hypertensive rat. 1976
    1976 Inhibition of proximal tubular hydrolysis and reabsorption of bradykinin by peptides 1976
    1976 Micropuncture evidence of rapid hydrolysis of bradykinin by rat proximal tubule 1976
    1976 Mineralocorticoids in normal pregnancy. 1976
    1976 The renin-angiotensin system in mother and fetus at cesarean section: a preliminary communication. 1976
    1976 Theoretical approaches to estimation of plasma renin activity: a review and some original observations 1976
    1976 Managing heart disease in pregnancy. 1976
    1976 Catecholamines, blood pressure, renin and myocardial function in the spontaneously hypertensive rat 1976
    1976 Digitalis assay and its clinical application 1976
    1976 Effects of renal hemodynamics on metabolism of angiotensin II (AII) by the dog kidney 1976
    1976 Inhibition of proximal tubular hydrolysis and reabsorption of angiotensin II by amino acid 1976
    1976 Inhibition of proximal tubular hydrolysis of bradykinin 1976
    1976 Myocardial function and renin in the spontaneously hypertensive rat after central and peripheral sympathectomy 1976
    1976 Oral-Contraceptive-Induced Hypertension After Adrenalectomy and Hypophysectomy 1976
    1976 Regulation of cortisol (F) secretion in pregnancy 1976
    1976 Structural requirements for the inhibition of renin release in vitro by the angiotensins 1976
    1976 Treatment of essential hypertension with a combination of hydrochlorothiazide, propranolol and methyldopa 1976
    1975 Effect of progesterone on renal sodium handling in man: relation to aldosterone excretion and plasma renin activity 1975
    1975 Fate of labeled angiotensin II microinfused into individual nephrons in the rat 1975
    1975 Oral contraceptive pill hypertension 1975
    1975 Plasma renin activity in hypertension. 1975
    1975 Central catecholamine depletion and the prevention of hypertension 1975
    1975 Handling of small peptides by rat renal tubules 1975
    1975 Physician acceptance of computer recommended antihypertensive therapy 1975
    1975 Prevention of Hypertension in the SH Rat: Effects of Differential Central Catecholamine Depletion 1975
    1974 Studies of plasma bradykininases using radiolabelled substrates 1974
    1974 The Renin-Angiotensin System 1974
    1974 The Renin-Angiotensin System 1974
    1974 The renin-angiotensin system (first of two parts). 1974
    1974 Effects of ph and enzyme inhibitors on apparent generation of angiotensin i in human plasma 1974
    1974 New polypeptide inhibitors of angiotensin conversion 1974
    1974 Structural requirements for substrates and inhibitors of angiotensin I converting enzyme in vivo and in vitro 1974
    1973 Heart disease in pregnancy 1973
    1973 Mechanism of renal handling of angiotensin II in the dog 1973
    1973 Metabolism of angiotensin II (AII) by dog kidney 1973
    1973 Polypeptide inhibitors of angiotensin converting enzyme 1973
    1973 Substrate requirements for angiotensin I conversion in vivo and in vitro. 1973
    1972 Left-Superior-Vena-Cava Steal Syndrome 1972
    1971 Mechanism of pulmonary conversion of angiotensin I to angiotensin II in the dog. 1971
    1971 Renin in differential diagnosis of hypertension 1971
    1970 In-vivo and in-vitro conversion of angiotensin I to angiotensin II in dog blood. 1970
    1970 Role of renin in acute postural homeostasis. 1970
    1966 Sex difference in fluid exchange during food deprivation in the rabbit. 1966

    Book

    Year Title Altmetric
    2018 Impact of the SPRINT Trial on Hypertension Management.  Ed. 69.  2018
    2005 Preface 2005
    2005 Preface to the First Edition 2005
    2005 Hypertension 2005

    Chapter

    Year Title Altmetric
    2018 Hypertension in women.  35-47. 2018
    2013 Hypertension and cardiovascular risk.  183-194. 2013
    2013 Pathogenesis of Hypertension.  12-26. 2013
    2012 Epidemiology of hypertension.  45-54. 2012
    2012 Initial evaluation and approach to the patient with hypertension.  463-473. 2012
    2012 Renin-angiotensin- aldosterone inhibitors in combination therapy.  53-64. 2012
    2010 Hypertensive Emergencies.  355-367. 2010
    2007 Fixed Low-Dose Antihypertensive Therapy.  1061-1073. 2007
    2007 Oral Contraceptives, Hormone Replacement Therapy, and Hypertension.  865-882. 2007
    2007 Pathophysiology of Hypertension.  25-46. 2007
    2007 Treatment of Hypertension in the Patient with Cardiovascular Disease.  625-646. 2007
    2005 Ischemic Heart Disease.  567-578. 2005
    2005 The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  340-351. 2005
    2005 The LIFE Study.  352-365. 2005
    2004 Hypertension and Sympathetic Nervous System Activity.  241-244. 2004

    Research Overview

  • Dr. Oparil's longstanding research interests include: lifestyle modification as an approach to prevent and treat cardiovascular diseases (CVDs), the aging heart and aging-associated predictors of chronic disease, pathophysiology and treatment of high blood pressure, the effects of aging on CVD in women and the relation between estrogen withdrawal and increase of CVD risk in postmenopausal women.

    Dr. Oparil has made many seminal contributions to vascular biology and hypertension research and has an impressive publication record of > 850 peer-reviewed articles on topics in clinical cardiology, atherosclerosis, heart failure, cardiovascular pathologies related to aging, vascular biology and hypertension and population science related to cardiovascular diseases.
  • Principal Investigator On

  • Mechanisms of Hypertension and Cardiovascular Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2021
  • 30th Annual Vascular Biology and Hypertension Symposium  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2019 - 2020
  • Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)  awarded by Brigham and Women's Hospital 2017 - 2020
  • Private Grant  awarded by Bayer HealthCare 2015 - 2019
  • Blood Pressure and Kidney Function - SPRINT vs Electronic Health Record Data  awarded by University of Minnesota 2017 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2017 - 2018
  • Systolic Blood Pressure Intervention Trial (SPRINT) Clinical Center Networks  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2009 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2017
  • Private Grant  awarded by ASTRAZENECA AB 2013 - 2016
  • A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus (EXSCEL)  awarded by DUKE CLINICAL RESEARCH INSTITUTE 2010 - 2016
  • Mechanisms of Hypertension and Cardiovascular Diseases  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by Bayer HealthCare 2016
  • TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy  awarded by Duke University 2009 - 2015
  • Private Grant  awarded by Bayer HealthCare 2014 - 2015
  • Private Grant  awarded by ARBOR PHARMACEUTICALS, LLC. 2014
  • O-GlyNAcylation: Novel Mechanism of Estrogen-Induced Vasoprotection  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2009 - 2013
  • Private Grant  awarded by AMARIN PHARMA, INC. 2013
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2013
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2010 - 2013
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2011 - 2013
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012
  • Private Grant  awarded by VIVUS, INC. 2012
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2012
  • Private Grant  awarded by AMGEN, INC. 2010 - 2011
  • Private Grant  awarded by DAIICHI SANKYO, INC. 2011
  • Integrated Regulation of Extracellular Matrix Expression in Cardiac Fibroblasts  awarded by American Heart Association 2010 - 2011
  • Mechanisms of Hypertension and Cardiovascular Diseases  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2006 - 2011
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2009 - 2011
  • Investigator On

  • Matrikines and COPD-PH  awarded by NIH - National Institutes of Health/DHHS 2019 - 2024
  • Private Grant  awarded by IDORSIA PHARMACEUTICALS LTD 2018 - 2023
  • Private Grant  awarded by ROX MEDICAL INC. 2018 - 2023
  • Private Grant  awarded by VASCULAR DYNAMICS INC. 2018 - 2023
  • Private Grant  awarded by RECOR MEDICAL 2016 - 2023
  • Evaluating Novel Approaches for Estimating Awake and Sleep Blood Pressure  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2022
  • Diastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of Chronic Obstructive Pulmonary Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2021
  • Mechanisms of Salt-Dependent Shifts in Blood Pressure Rhythms  awarded by American Heart Association 2019 - 2021
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2011 - 2020
  • Chronic Hypertension and Pregnancy-CHAP Clinical Coordinating Center  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2020
  • Private Grant  awarded by GE HEALTHCARE 2018 - 2020
  • Collaboration to Improve Blood Pressure (BP) in the US Black Belt - Addressing the Triple Threat  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2015 - 2020
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2017 - 2020
  • Sustained Blood Pressure Control and Progression of Multimorbidity  awarded by Duke University 2017 - 2020
  • Neutrophil Dysregulation as a Driving Mechanism of Cardiovascular Disease in HIV-1-Infection  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2020
  • University of Alabama at Birmingham Strategically Focused Hypertension Research Center - Mechanisms of Nocturnal Hypertension and Non-Dipping Blood Pressure - Project 2  awarded by American Heart Association 2015 - 2020
  • Mechanisms of Refractory Hypertension  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2020
  • Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)  awarded by Brigham and Women's Hospital 2016 - 2020
  • The SPRINT· Alzheimer's, Seniors, and Kidney Study (SPRINT ASK)  awarded by WAKE FOREST UNIVERSITY 2017 - 2019
  • Cardiovascular Inflammation Reduction Trial (CIRT)  awarded by Brigham and Women's Hospital 2013 - 2019
  • University of Alabama at Birmingham Strategically Focused Hypertension Research Center  awarded by American Heart Association 2015 - 2019
  • Targeted Cell Therapy for Acute Lung Injury  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2018
  • Private Grant  awarded by GE HEALTHCARE 2017 - 2018
  • Private Grant  awarded by GEORGE CLINICAL 2017 - 2018
  • Private Grant  awarded by MEDTRONIC, INC. 2012 - 2018
  • Targeted Delivery of iPS-Endothelial Cells for the Repair of Cardiovascular Injury  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2013 - 2018
  • Centers of Research Translation (CoRT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Centers of Research Translation (CoRT) - Project 2  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Visit-to-Visit Variability of Blood Pressure and CVD and Renal Outcomes  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2012 - 2016
  • Private Grant  awarded by TRIVASCULAR, INC. 2010 - 2015
  • Training Program in Cardiovascular Pathophysiology  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2015
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2015
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2013 - 2014
  • Maintenance of Organ Function Following Injury  awarded by National Institute of General Medical Sciences/NIH/DHHS 2009 - 2014
  • Etiology of Sleep Apnea-Related Hyperaldosteronism  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2008 - 2014
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2011 - 2013
  • Cardiovascular Tissue and Cell Core  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2009 - 2013
  • Genetics of Hypertension Associated Treatment (GENHAT)  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2007 - 2012
  • Education And Training

  • Presbyterian Hospital, Internship 1966
  • Massachusetts General Hospital, Residency 1968
  • Presbyterian Hospital, Residency 1967
  • Massachusetts General Hospital, Postdoctoral Fellowship 1971
  • Full Name

  • Suzanne Oparil